Laying the Foundations for Long Term Remission in High-Risk AML*
*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Thursday 29th October, 12:30 – 13:00
| Duration | Title | Speaker |
| 2 mins | Welcome and Introduction | Prof Alessandro Isidori, Italy |
| 24 mins | Laying the Foundation for Long Term Remission in High-Risk AML* | Dr Donal McLornan, UK |
| 4 mins | Summary and Close | Prof Alessandro Isidor, Italy |
This symposium is funded and organised by Jazz Pharmaceuticals.
This symposium will contain promotional content and prescribing information will be shown at the end of each presentation and at the end of the symposium.
This symposium is intended for healthcare professionals only.
|
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765 |